- Home
- PLX vs BWG Comparison
PLX vs BWG Comparison
Compare PLX & BWG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- BWG
- Stock Information
- Founded
- PLX 1993
- BWG 2012
- Country
- PLX United States
- BWG United States
- Employees
- PLX N/A
- BWG N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- BWG Finance/Investors Services
- Sector
- PLX Health Care
- BWG Finance
- Exchange
- PLX Nasdaq
- BWG Nasdaq
- Market Cap
- PLX 160.2M
- BWG 140.2M
- IPO Year
- PLX 1998
- BWG N/A
- Fundamental
- Price
- PLX $1.58
- BWG $8.03
- Analyst Decision
- PLX Strong Buy
- BWG
- Analyst Count
- PLX 1
- BWG 0
- Target Price
- PLX $15.00
- BWG N/A
- AVG Volume (30 Days)
- PLX 1.4M
- BWG 53.8K
- Earning Date
- PLX 05-09-2025
- BWG 01-01-0001
- Dividend Yield
- PLX N/A
- BWG 11.37%
- EPS Growth
- PLX N/A
- BWG N/A
- EPS
- PLX 0.05
- BWG N/A
- Revenue
- PLX $59,764,000.00
- BWG N/A
- Revenue This Year
- PLX $65.02
- BWG N/A
- Revenue Next Year
- PLX $57.34
- BWG N/A
- P/E Ratio
- PLX $32.18
- BWG N/A
- Revenue Growth
- PLX 0.18
- BWG N/A
- 52 Week Low
- PLX $0.82
- BWG $6.86
- 52 Week High
- PLX $3.10
- BWG $8.65
- Technical
- Relative Strength Index (RSI)
- PLX 30.32
- BWG 51.10
- Support Level
- PLX $1.52
- BWG $8.01
- Resistance Level
- PLX $1.79
- BWG $8.22
- Average True Range (ATR)
- PLX 0.09
- BWG 0.07
- MACD
- PLX -0.01
- BWG -0.01
- Stochastic Oscillator
- PLX 26.44
- BWG 61.29
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About BWG BrandywineGLOBAL Global Income Opportunities Fund Inc.
BrandywineGLOBAL - Global Income Opportunities Fund Inc is a non-diversified, closed-end management investment company. The primary investment objective is to provide current income. The secondary investment objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing, under normal market conditions, at least 80% of its assets in world-wide fixed-income securities.